2023 World Conference on Lung Cancer (Posters)-P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations

P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the clinical characteristics and outcomes of patients with EGFR-mutant lung cancer who developed acquired BRAF alterations following treatment with EGFR tyrosine kinase inhibitors (TKIs). The researchers collected data from patients with EGFR-mutant non-small cell lung cancer (NSCLC) with acquired BRAF alterations at Memorial Sloan Kettering Cancer Center between January 2014 and January 2023.<br /><br />The study found that acquired BRAF alterations were identified in patients with acquired resistance to EGFR TKIs. The patients were treated with combinations of EGFR TKIs and RAF/MEK inhibitors. The researchers observed that treatment with osimertinib with RAF/MEK inhibitor or erlotinib with trametinib resulted in dose reduction in 53% of patients. Furthermore, 26% of patients experienced adverse events (TRAEs) that required permanent treatment discontinuation, including fever, pneumonitis, fatigue, and mucositis.<br /><br />The overall survival of patients with acquired BRAF alterations was assessed using the Kaplan-Meier method. The study found that further exploration of drug combinations is warranted to investigate the tolerability of treatment for patients with EGFR-mutant lung cancer with acquired BRAF alterations. The results of this study provide insight into the clinical and treatment outcomes of these patients.<br /><br />In conclusion, this study sheds light on the clinical characteristics and treatment outcomes of patients with EGFR-mutant lung cancer who developed acquired BRAF alterations after treatment with EGFR TKIs. The findings suggest that additional research is needed to explore drug combinations for these patients and improve the tolerability of treatment.

Asset Subtitle

Jane Sui

Meta Tag

Speaker Jane Sui

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR-mutant lung cancer

acquired BRAF alterations

EGFR tyrosine kinase inhibitors

clinical characteristics

patient outcomes

non-small cell lung cancer

osimertinib

erlotinib

RAF/MEK inhibitors

adverse events